Updated recommendations on the use of herpes zoster vaccines .: HP40-212/2018E-PDF
"The need for this updated National Advisory Committee on Immunization (NACI) Advisory Committee Statement on the Use of Herpes Zoster (HZ) Vaccines was triggered by evidence on a newly authorized Recombinant subunit Zoster Vaccine (RZV) vaccine, Shingrix®, indicated for the prevention of HZ in individuals 50 years of age and older. The primary objective of this statement is to review current evidence and develop guidance on the use of Shingrix®, as well as to provide guidance on whether the previously authorized Live Zoster Vaccine (LZV), Zostavax®II, and/or the recently authorized RZV should be offered to Canadians ≥50 years of age and older"--Introd., p. 6.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.853982&sl=0
| Department/Agency | Public Health Agency of Canada. Infectious Disease Prevention and Control Branch. |
|---|---|
| Title | Updated recommendations on the use of herpes zoster vaccines . |
| Variant title | At head of title: Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Issued also in French under title: Recommandations à jour sur l’utilisation des vaccins contre le zona. Includes bibliographic references: p. 63-72. |
| Publishing information | Ottawa : Public Health Agency of Canada,2018. |
| Description | 177 p. : col. charts. |
| ISBN | 9780660258522 |
| Catalogue number |
|
| Departmental catalogue number | Pub.: 170531 |
| Subject terms | Immunization Infectious diseases |